---
document_datetime: 2025-08-08 13:44:14
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cystadrops-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: cystadrops-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.0883568
conversion_datetime: 2025-12-18 20:30:52.104742
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Cystadrops

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------|
| II/0032              | Extension of indication to include treatment of children from 6 months of age for Cystadrops, based on final results from study CYT-C2-001. This is an open-label, single-arm, multicenter study to assess the safety of Cystadrops in paediatric cystinosis patients from 6 months to less than 2 years old. As a | 25/04/2025                          | 06/06/2025                                  | SmPC, Annex II and PL            | Please refer to Scientific Discussion 'Cystadrops-H-C- 00003769-II-32' |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the PI and the list of local representatives in the Package Leaflet. The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |                                  |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IAIN/0033/G         | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                      | 10/12/2024 | 06/06/2025 | SmPC, Annex II, Labelling and PL |                                   |
| IA/0031             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                | 01/10/2024 | n/a        |                                  |                                   |
| PSUSA/10574 /202401 | Periodic Safety Update EU Single assessment - mercaptamine (Indicated for the treatment of corneal cystine crystal deposit only)                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 05/09/2024 | n/a        |                                  | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0028   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                             | 06/12/2023   | n/a   |           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------|
| IB/0027   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                         | 09/11/2023   | n/a   |           |
| IA/0025/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 16/01/2023   | n/a   | procedure |
| IA/0024   | B.II.a.3.b.1 - Changes in the composition (excipients) of the finished product - Other excipients - Any minor adjustment of the quantitative composition of the finished product with respect to excipients                                                                                                                                                                                                                                                                                  | 22/06/2022   | n/a   |           |

<div style=\"page-break-after: always\"></div>

| II/0023             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   | 07/04/2022   | n/a        |                                  |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------|
| R/0022              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                          | 22/07/2021   | 15/09/2021 | SmPC, Labelling and PL           |                                   |
| PSUSA/10574 /202101 | Periodic Safety Update EU Single assessment - mercaptamine (Indicated for the treatment of corneal cystine crystal deposit only)                                                                                                                                                                 | 02/09/2021   | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0020             | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                       | 15/10/2020   | n/a        |                                  |                                   |
| IB/0019             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                              | 23/09/2020   | 15/09/2021 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/10574 /202001 | Periodic Safety Update EU Single assessment - mercaptamine (Indicated for the treatment of corneal cystine crystal deposit only)                                                                                                                                                                 | 03/09/2020   | n/a        |                                  | PRAC Recommendation - maintenance |
| N/0017              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                 | 26/05/2020   | 15/09/2021 | PL                               |                                   |
| IA/0016             | B.I.b.2.a - Change in test procedure for AS or                                                                                                                                                                                                                                                   | 24/03/2020   | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| PSUSA/10574 /201901 | Periodic Safety Update EU Single assessment - mercaptamine (Indicated for the treatment of corneal cystine crystal deposit only)                                                                                                                                                                                                                                                                                                                                                                                                          | 05/09/2019 | n/a        |                                  | PRAC Recommendation - maintenance |
| IG/1085/G           | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 16/05/2019 | 04/05/2020 | SmPC, Annex II, Labelling and PL |                                   |
| N/0013              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/02/2019 | 04/05/2020 | PL                               |                                   |
| PSUSA/10574 /201807 | Periodic Safety Update EU Single assessment - mercaptamine (Indicated for the treatment of corneal cystine crystal deposit only)                                                                                                                                                                                                                                                                                                                                                                                                          | 14/02/2019 | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0012/G           | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished                                                                                                                                                                                                                                                                                                                                                                                                                                 | 15/01/2019 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|                     | product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                            |            |            |                  |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|-----------------------------------|
| IA/0011/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 19/12/2018 | n/a        |                  |                                   |
| N/0009              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                         | 07/11/2018 | 04/05/2020 | PL               |                                   |
| PSUSA/10574 /201801 | Periodic Safety Update EU Single assessment - mercaptamine (Indicated for the treatment of corneal cystine crystal deposit only)                                                                                                                                                                                                                                                         | 06/09/2018 | n/a        |                  | PRAC Recommendation - maintenance |
| N/0007              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                         | 30/05/2018 | 04/05/2020 | Labelling and PL |                                   |
| IB/0006/G           | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of                                                                                                                                                                                                                                                                                   | 08/03/2018 | n/a        |                  |                                   |

<div style=\"page-break-after: always\"></div>

|                     | the AS - Minor change to the restricted part of an ASMF B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                         |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10574 /201707 | Periodic Safety Update EU Single assessment - mercaptamine (Indicated for the treatment of corneal cystine crystal deposit only)                                                                                                                                                                                                                                                                                                                                                                                | 08/02/2018 | n/a | PRAC Recommendation - maintenance |
| IA/0003/G           | This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test | 11/09/2017 | n/a |                                   |
| IA/0002/G           | This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished                                                                                                                                                                                                                  | 10/08/2017 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|             | product - Deletion of a non-significant in-process test                                                                                                                                                                                                                                               |            |            |                 |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IAIN/0001/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer | 16/02/2017 | 11/01/2018 | Annex II and PL |